Get the Daily Brief
Latest Biotech News
Regulatory and payer pressure on GLP-1 access for older Americans
The Trump administration launched the Medicare GLP-1 Bridge program, setting a monthly cost cap of $50 for three weight-loss drugs—Wegovy, the tirzepatide KwikPen version of Zepbound, and...
Reliability of compounding GLP-1 supply amid ongoing demand
A new JAMA Health Forum investigation reports that even as shortages for semaglutide and tirzepatide ease, compounded GLP-1 products continue to be produced using added ingredients, with supply...
FDA decision fallout in refractory chronic cough
GSK moved to shut down camlipixant after mixed Phase 3 results in refractory chronic cough (RCC). The company said the pill is unlikely to transform patient care, and it will discontinue the...
Oncology trial design: timing of immune checkpoint inhibitors
A new analysis in the British Journal of Cancer links overall survival to the timing of immune checkpoint inhibitor dosing in advanced cancers. Rather than focusing only on whether immunotherapy...
Pancreatic cancer interception: KRAS-targeted vaccine first milestone
A Phase I trial of a KRAS-mutant vaccine for pancreatic cancer interception cleared an early efficacy-and-safety milestone by inducing KRAS-specific T-cell responses in 90% of high-risk...
Duchenne gene therapy: EMA denial triggers new Phase III attempt
Sarepta launched an additional Phase III trial for Elevidys after the EMA denied marketing authorization based on evidence concerns from the prior program. While the therapy received FDA approval...
Bridging neuroscience to aging: EP2 pathway and senescent neutrophil clearance
Researchers at Stanford Medicine tied organ aging to impaired immune clearance by tissue-resident macrophages (TRMs), identifying EP2 signaling as a key control point. In Science, the team...
Gene therapy platform innovation: engineered circRNA for longer protein expression
Circio Holding and Avenue Biosciences agreed to combine Circio’s circVec platform with Avenue’s protein engineering capabilities to improve long-term expression and secretion of therapeutic...
Biopharma M&A: record first-half deal value
Biopharma’s record-breaking first half continued with June delivering the second-strongest month of H1 deal value. Through the first six months of 2026, deal value reached $170.11 billion,...
Company expansion via acquisition: Leica to buy Statlab
Leica Biosystems, part of Danaher, agreed to acquire Statlab Medical Products to expand Danaher’s diagnostics and anatomical pathology footprint. The deal strengthens access to a broader mix of...
Regulatory setbacks in respiratory drugs
GSK moved to shut down camlipixant after its Phase 3 program in refractory chronic cough delivered mixed results. The drug met the primary endpoint in one Calm-1 experiment but missed goals in...
Immunotherapy dosing strategy linked to survival
A new analysis in the British Journal of Cancer suggests the timing of immune checkpoint inhibitor dosing can influence overall survival in advanced cancer. Instead of focusing only on whether...
Oncology: vaccine interception for pancreatic cancer risk
A Phase I trial reported a first-in-human proof of concept for KRAS-mutant vaccination to intercept pancreatic cancer development in high-risk patients. In Cancer Discovery, investigators reported...
Aging biology: macrophage EP2 signaling as a lever on organ decline
Stanford Medicine researchers reported in Science that restoring senescent-neutrophil clearance by tissue-resident macrophages can limit organ-wide aging in mice and preserve youth-like function....
Oncology diagnostics and theranostics: ctDNA to select radium-223 patients
A study in The Journal of Nuclear Medicine reported that circulating tumor DNA profiling can better select patients for radium-223 (^223Ra) radiopharmaceutical therapy in metastatic...
Data-driven early identification in preterm lung disease
Researchers reported a machine-learning system that predicts bronchopulmonary dysplasia (BPD) seven days after birth using respiratory data. The study, published in Pediatrics, targets a...
Regenerative medicine: fibroblast reprogramming barrier identified
A 2026 Nature Communications study identified sulfotransferase signaling as a molecular brake that helps fibroblasts maintain identity and blocks cardiac reprogramming. The work links a specific...
Gene editing: AI-designed TnpB expands CRISPR toolbox
In Science, researchers described an AI-designed synthetic TnpB enzyme (SynTnpBs) that outperformed a natural reference transposase. The advance extends beyond standard CRISPR-Cas systems by...
Duchenne gene therapy: EMA resubmission push with added Phase III trial
Sarepta launched an additional Phase III trial for its Duchenne muscular dystrophy gene therapy Elevidys to address prior European Medicines Agency marketing authorization concerns. The move...
Diagnostics and platform expansion: Leica to buy Statlab in pathology
Leica Biosystems agreed to acquire Statlab Medical Products to expand Danaher’s diagnostics and anatomical pathology portfolio. The deal strengthens Leica’s consumables and instrument footprint in...